推荐产品
生物来源
mouse
质量水平
偶联物
ALEXA FLUOR™ 488
抗体形式
purified antibody
抗体产品类型
primary antibodies
克隆
JBW301, monoclonal
种属反应性
human
种属反应性（根据同源性预测）
vertebrates (based on 100% sequence homology)
技术
immunocytochemistry: suitable
同位素/亚型
IgG1
NCBI登记号
UniProt登记号
运输
wet ice
靶向翻译后修饰
phosphorylation (pSer139)
基因信息
human ... H2AX(3014)
一般描述
组蛋白H2A.X是组蛋白H2A的变体，与基因组DNA相似。但是，组蛋白在结构上与H2A家族的其他成员不同，因为它具有一个C末端尾巴，该尾巴包含Ser139残基，该残基响应于双链DNA的断裂而被磷酸化。H2A.X的磷酸化是由ATM/ATR蛋白介导的快速过程。
应用
该抗磷酸化组蛋白H2A.X（Ser139）抗体（克隆JBW301，Alexa Fluor™ 488偶联物）经验证可用于ICC检测磷酸化组蛋白H2A.X（Ser139）。
质量
通过免疫细胞化学在未处理（阴性对照）和星形孢菌素处理的HeLa细胞中进行评估。
免疫细胞化学分析：来自代表性批次的1:100稀释液在星形孢菌素处理的HeLa细胞中检测到磷酸组蛋白H2A.X（Ser139），而在未处理的HeLa细胞中未检测到。
免疫细胞化学分析：来自代表性批次的1:100稀释液在星形孢菌素处理的HeLa细胞中检测到磷酸组蛋白H2A.X（Ser139），而在未处理的HeLa细胞中未检测到。
目标描述
计算分子量为17 kDa
其他说明
浓度：请参考批次特异性浓缩物的分析证书。
法律信息
ALEXA FLUOR is a trademark of Life Technologies
未找到合适的产品？
试试我们的产品选型工具.
储存分类代码
12 - Non Combustible Liquids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Chien-Hsing Chang et al.
Molecular cancer therapeutics, 15(8), 1910-1919 (2016-05-22)
Sacituzumab govitecan (IMMU-132), an SN-38-conjugated antibody-drug conjugate, is showing promising therapeutic results in a phase I/II trial of patients with advanced Trop-2-expressing, metastatic, solid cancers. As members of the ATP-binding cassette (ABC) transporters confer chemotherapy resistance by active drug efflux
Huan Zhang et al.
Frontiers in oncology, 12, 999302-999302 (2022-12-17)
Poly(ADP-ribose) (PAR) polymerase inhibitors (PARPi) either have been approved or being tested in the clinic for the treatment of a variety of cancers with homologous recombination deficiency (HRD). However, cancer cells can develop resistance to PARPi drugs through various mechanisms
Lara H El Touny et al.
Oncotarget, 12(21), 2114-2130 (2021-10-23)
The therapeutic efficacy of temozolomide (TMZ) is hindered by inherent and acquired resistance. Biomarkers such as MGMT expression and MMR proficiency are used as predictors of response. However, not all MGMTlow/-ve/MMRproficient patients benefit from TMZ treatment, indicating a need for
Jolien Van den Bossche et al.
Cancers, 11(12) (2019-12-05)
Polo-like kinase 1 (Plk1), a master regulator of mitotic cell division, is highly expressed in non-small cell lung cancer (NSCLC) making it an interesting drug target. We examined the in vitro therapeutic effects of volasertib, a Plk1 inhibitor, in combination
Lidia F Hernandez et al.
Cell death discovery, 7(1), 134-134 (2021-06-06)
Ovarian cancer is the most lethal gynecological cancer in the US. Standard treatment consists of surgery followed by chemotherapies relying on apoptotic tumor cell death. Most women with advanced stage disease will relapse, suggesting that this disease is characterized by
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门